AbbVie, Gilead Sciences, Pfizer, and Roche are among the companies that must cut a check to the U.S. government. Those companies have Medicare-covered medicines whose prices rose faster than inflation and according to a…
Continue Reading
The telehealth flexibilities allowed during the Covid-19 public health emergency greatly expanded access to healthcare services. But after the public health emergency ends, it’s ultimately up to Congress to further extend these flexibilities, said…
Continue Reading
Novo Nordisk is slashing prices of several insulin products by up to 75% amid growing political scrutiny on the prices of these older but still expensive diabetes medicines. The announcement Tuesday comes two weeks…
Continue Reading
Pharmacy benefit managers (PBMs) are being targeted yet again by the government. James Comer (R-Ky), House Committee on Oversight and Accountability chairman, launched an investigation Wednesday into PBMs and their “tactics that are harming…
Continue Reading
Eli Lilly is cutting insulin prices, and this time it’s for real.
Months after a Twitter account posing as the drugmaker went viral with a tweet stating, “insulin is free now,” the company on Wednesday…
With the Inflation Reduction Act now on the books, the U.S. Centers for Medicare & Medicaid Services (CMS) will begin negotiating drug prices with the pharmaceutical industry. That, combined with other headwinds such as increased competition from me-too drugs, and ever-present pricing pressure from payers, means that pharma players now more than ever need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Learning from the auto industry Almost every industry has had to confront a fundamental existential question: What is our product? Consider the automotive industry, which once was largely about hardware…
The U.S. Department of Health & Human Services (HHS) unveiled three new models Tuesday that will be tested by the CMS Innovation Center and aim to lower prescription drug costs. The models include access to $2 generic drugs.
The news is in response to President Joe Biden’s executive order issued in October, which directed HHS to find ways to lower prescription drug costs and improve access to drug therapies for those enrolled in Medicare and Medicaid health plans. The models are meant to build on the Inflation Reduction Act of 2022, which includes allowing Medicare to negotiate lower prescription drug prices for…
It’s a new year, and healthcare technology vendors are rolling out their latest innovations, market approvals, acquisitions and staffing shake-ups.OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. A suite of new tools for both patients and providers target aspects of pharmacy logistics that have been known to delay or complicate care, such as getting real-time pharmacy benefits information and obtaining prior authorizations. In October, Optum, UnitedHealth Group’s pharmacy services company, merged with data clearinghouse Change Healthcare. The U.S. Department of Justice tried to block the merger and is appealing the…
Continue Reading
